Received: 5 February 2020
Accepted: 24 April 2020
First Online: 17 June 2020
Ethics approval and consent to participate
: The Institutional Review Board at Lund, Sweden, approved the study (id nr: 89: 2007). All study participants signed an informed consent
: Prof. Rutger Persson and Dr Ahmad Aghazadeh declare no conflict of interest. Prof. Stefan Renvert states research grants and fees from Geistlich Pharma outside the present work.